Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review
Despite the initial shock of the COVID-19 pandemic, 2020 was a standout year for biopharma. The top 600 biopharma companies added $487bn in market capitalisation, and smaller biotechs saw a record-breaking $12.8bn raised by IPO and $20bn invested by venture financers. Fortunes in the medical device industry were more divided. Companies developing…
Report library
Evaluate Vantage 2021 Preview
Biopharma’s role in trying to bring the COVID-19 pandemic to an end has made household names of companies large and small, and cutting-edge technologies like mRNA…
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
Biopharma was not exempt from the initial shock of a global pandemic, but the worst projections have not happened and the initial beneficiaries have now emerged. After a…
Evaluate Pharma World Preview 2020, Outlook to 2026
This year's edition of the Evaluate Pharma World Preview arrives at a time when the global economy is reeling. The impact of COVID-19 has so far wiped $7.85bn off…
Evaluate Vantage COVID-19 Report
Biopharma and Medtech are leading the fight against COVID-19, but are not immune from the significant economic impact of the pandemic. The COVID-19 pandemic is having a…
Evaluate Pharma Orphan Drug Report 2020
What will the orphan drug landscape look like in 2024? Big pharma's recent dominance of the orphan market has fuelled calls to reform the orphan drug act in the US.…
